HNF4A-MODY and Its Newborn Twist

HNF4A-MODY, also called MODY1, was the second commonest subtype in an Asian Indian clinic study, accounting for 29.4% of confirmed cases.

In adults it looks much like HNF1A-MODY: young onset in a lean person, with predominantly raised post-meal glucose and progressive beta-cell decline. And like HNF1A, it responds well to low-dose sulfonylureas — better than to metformin.

What sets it apart happens before the diagnosis is ever made, at birth.

Around half of HNF4A-MODY carriers are born unusually large. The mechanism is initially counterintuitive: as newborns they produce too much insulin, which both drives extra growth in the womb and causes low blood sugar after birth. One study found macrosomia in 56% of HNF4A carriers against 13% of unaffected family members, with a median birth weight around 790 g higher, and persistent newborn low blood sugar in 15.4%.

So the same gene that causes too little insulin in adulthood causes too much in the newborn period.

This has two practical uses. A family history of unusually large babies alongside young-onset diabetes is a genuine clue pointing at HNF4A. And if a pregnant woman is known to carry it, the baby needs blood-sugar monitoring for at least 48 hours after delivery.